Company Focus
BioNTech
Latest BioNTech News
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Related News
Insights
Company Spotlight
A Canadian biotech company focussed on utilising lipid nanoparticle (LNP) for nucleic acid delivery.
Latest News & Features of interest to BioNTech
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. 18 December 2024
Pharmaceutical
ENA Respiratory, an Australian pharma developing innate immune modulators to prevent complications associated with respiratory viral infections in at-risk populations, has announced the publication of results of its Phase IIa study with its liquid formulation of INNA-051 in ERJ Open Research. 18 December 2024
Pharmaceutical
In significant efforts to strengthen public health and improve vaccine access in Africa, the US International Development Finance Corporation, the African Development Bank and the International Finance Corporation (IFC) have jointly announced a $45 million financing package for VaxSen, a subsidiary of Senegal’s Institut Pasteur de Dakar (IPD). 18 December 2024
Biotechnology
China's drug regulator has approved clinical trials for an experimental mpox vaccine developed by Sinopharm, marking a significant step in the country’s efforts to offer an alternative jab. 17 December 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for clesrovimab (MK-1654), Merck & Co’s prophylactic long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season. 17 December 2024
Biotechnology
Danish vaccine maker Bavarian Nordic has signed a licensing and manufacturing agreement with the Serum Institute of India (SII) to expand production capacity for its mpox vaccine Jynneos. 17 December 2024
Biotechnology
Cell therapy specialist Candid Therapeutics has entered a strategic collaboration with Shanghai-based EpimAb Biotherapeutics to discover and develop new T-Cell engager (TCE) candidates. 17 December 2024
Pharmaceutical
Japanese drugmaker Kyorin Pharmaceutical has entered into a licensee agreement with Bayer for the novel obstructive sleep apnea (OSA) treatment BAY2925976 and its backup compound discovered by the German pharma major. 17 December 2024
Pharmaceutical
UK-based PureTech Health has announced positive results from ELEVATE IPF, a Phase IIb trial of deupirfenidone (LYT-100) at two dose levels, three times a day (TID) over 26 weeks in patients with idiopathic pulmonary fibrosis (IPF). 16 December 2024
Latest In Brief for BioNTech
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Latest Relevant Ones To Watch News
Japanese drugmaker Shionogi has announced that it will acquire full ownership of its joint ventures with subsidiaries of Ping An Insurance. 23 December 2024
3 December 2024
29 November 2024
21 November 2024
19 November 2024
15 November 2024
18 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze